The author is a salaried employee at Amgen Inc. and possesses stock and stock options in the company.
Pregnancy exposure registries: Academic opportunities and industry responsibility†
Article first published online: 23 DEC 2008
Copyright © 2008 Wiley-Liss, Inc.
Birth Defects Research Part A: Clinical and Molecular Teratology
Special Issue: A Festschrift in Honor of Professor Lewis B. Holmes
Volume 85, Issue 1, pages 93–101, January 2009
How to Cite
Wyszynski, D. F. (2009), Pregnancy exposure registries: Academic opportunities and industry responsibility. Birth Defects Research Part A: Clinical and Molecular Teratology, 85: 93–101. doi: 10.1002/bdra.20525
- Issue published online: 9 JAN 2009
- Article first published online: 23 DEC 2008
- Manuscript Accepted: 28 AUG 2008
- Manuscript Revised: 21 AUG 2008
- Manuscript Received: 26 JUN 2008
- Amgen Pregnancy Exposure Safety Team (APEST)
- congenital anomalies;
- drug exposure;
- drug safety;
Pregnancy exposure registries systematically evaluate pregnancies and outcomes exposed to a medicinal compound or device during the gestational period. Historically, such programs partner an academic institution with one or more pharmaceutical companies or are run solely by a pharmaceutical company. However, other examples abound. This article describes what a pregnancy exposure registry is, as well as selected methodological challenges they face, using real examples and applications. Birth Defects Research (Part A), 2009. © 2008 Wiley-Liss, Inc.